Journal: The Journal of Clinical Endocrinology and Metabolism

Article Title: Immunohistochemical Detection of Mutated BRAF V600E Supports the Clonal Origin of BRAF -Induced Thyroid Cancers Along the Spectrum of Disease Progression

doi: 10.1210/jc.2013-1408

Figure Lengend Snippet: A and D, Classic PTC, mutated for BRAF V600E. A, 3+ diffuse homogeneous immunostaining with VE1. D, Corresponding H&E staining. B and E, Classic PTC, wild type for BRAF V600E. B, 0 to 1+ immunostaining with VE1. E, Corresponding H&E staining. C and F, Poorly differentiated carcinoma mutated for BRAF V600E. C, 2+ diffuse homogeneous immunostaining with VE1. F, Corresponding H&E staining.

Article Snippet: IHC procedure Three tissue microarrays of PTCs, PDTCs, and ATCs (n = 74 tumors) and whole conventional tumor sections of ATCs (n = 17 tumors) were subjected to IHC analysis using the VE1 antibody directed against the BRAF V600E protein (Spring Bioscience, Pleasanton, California).

Techniques: Immunostaining, Staining

Journal: The Journal of Clinical Endocrinology and Metabolism

Article Title: Immunohistochemical Detection of Mutated BRAF V600E Supports the Clonal Origin of BRAF -Induced Thyroid Cancers Along the Spectrum of Disease Progression

doi: 10.1210/jc.2013-1408

Figure Lengend Snippet: A–E, Whole section of anaplastic carcinoma with associated PTC tall cell variant (PTC TCV). Both the PTC TCV and anaplastic components have BRAF V600E mutation. A, Low-power view with diffuse homogeneous 3+ immunostaining for VE1 in PTC TCV (top arrow) and anaplastic (bottom arrow) components. B, High-power view of the PTC TCV component showing 3+ VE1 immunostaining. D, Corresponding H&E staining for B. C, High-power view of anaplastic component showing 3+ VE1 immunostaining. E, Corresponding H&E staining for C.

Article Snippet: IHC procedure Three tissue microarrays of PTCs, PDTCs, and ATCs (n = 74 tumors) and whole conventional tumor sections of ATCs (n = 17 tumors) were subjected to IHC analysis using the VE1 antibody directed against the BRAF V600E protein (Spring Bioscience, Pleasanton, California).

Techniques: Variant Assay, Mutagenesis, Immunostaining, Staining

Journal: Head and Neck Pathology

Article Title: Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis

doi: 10.1007/s12105-020-01166-8

Figure Lengend Snippet: Direct sequencing group—methods

Article Snippet: Positive when score 1+ Open in a separate window Direct sequencing group—methods table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Study (year) Method Number of specimens Clone VE1 vendor Dilution/incubation Interpretation Note Abd Elmageed (2017) rt-PCR 130 Spring Bioscience 1:100/60 min Capper et al. method Chen (2018) Quantitative rt-PCR 40 GBI Biotechnology NA/NA Capper et al. method de Biase (2014) ASLNA-qPCR 20 Spring Bioscience NA/NA NA Jung (2015) PCR 467 Spring Bioscience 1:50/NA No or weak staining considered negative.

Techniques: Sequencing, Staining, Mass Spectrometry

Journal: Head and Neck Pathology

Article Title: Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis

doi: 10.1007/s12105-020-01166-8

Figure Lengend Snippet: PCR group—methods

Article Snippet: Positive when score 1+ Open in a separate window Direct sequencing group—methods table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Study (year) Method Number of specimens Clone VE1 vendor Dilution/incubation Interpretation Note Abd Elmageed (2017) rt-PCR 130 Spring Bioscience 1:100/60 min Capper et al. method Chen (2018) Quantitative rt-PCR 40 GBI Biotechnology NA/NA Capper et al. method de Biase (2014) ASLNA-qPCR 20 Spring Bioscience NA/NA NA Jung (2015) PCR 467 Spring Bioscience 1:50/NA No or weak staining considered negative.

Techniques: Quantitative RT-PCR, Staining, Sequencing

Journal: Head and Neck Pathology

Article Title: Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis

doi: 10.1007/s12105-020-01166-8

Figure Lengend Snippet: Papillary thyroid carcinoma, classic type (a) showing diffuse cytoplasmic VE1 expression with moderate intensity (b); Papillary thyroid carcinoma, invasive follicular variant (c) showing negative VE1 immunostain (d). Evaluation of VE1 immunostain in papillary thyroid carcinoma at low power (e) may be deceptive. Higher power examination confirms diffuse but weak VE1 positivity (f) in a case with confirmed BRAF V600E mutation by next generation sequencing (unpublished data). These examples utilized prediluted Roche Ventana VE1 monoclonal antibody (Indianapolis, IN, USA) on the Leica Bond Refine System (Buffalo Grove, IL, USA) at 60 min incubation time

Article Snippet: Positive when score 1+ Open in a separate window Direct sequencing group—methods table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Study (year) Method Number of specimens Clone VE1 vendor Dilution/incubation Interpretation Note Abd Elmageed (2017) rt-PCR 130 Spring Bioscience 1:100/60 min Capper et al. method Chen (2018) Quantitative rt-PCR 40 GBI Biotechnology NA/NA Capper et al. method de Biase (2014) ASLNA-qPCR 20 Spring Bioscience NA/NA NA Jung (2015) PCR 467 Spring Bioscience 1:50/NA No or weak staining considered negative.

Techniques: Expressing, Variant Assay, Mutagenesis, Next-Generation Sequencing, Incubation

Journal: Clinical, Cosmetic and Investigational Dermatology

Article Title: Emerging clinical applications of selected biomarkers in melanoma

doi: 10.2147/CCID.S49578

Figure Lengend Snippet: List of selected tissue biomarkers in melanoma

Article Snippet: BRAFV600E , Serine/threonine protein kinase , VE1 (Spring Bioscience) , 1:50 , C , None available , Detect the presence of BRAFV600E mutation.

Techniques: Concentration Assay, Control, Mutagenesis, Ubiquitin Proteomics

Journal: BMC Complementary and Alternative Medicine

Article Title: BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo

doi: 10.1186/s12906-017-1621-7

Figure Lengend Snippet: Combination of TAM with BD regulates expression of apoptosis and TAM resistance related proteins in human breast tumors. Animal experiments were performed as described in Fig. . Paraffin-embedded tumor tissue sections were analyzed by immunohistochemistry using antibodies against BRAF, p21, Bcl-2 and Fibronectin (FN). Representative localization and intensity of immunoreactivities against all primary antibodies are shown. Immunohistochemical quantification of BRAF, p21, Bcl-2 and FN were determined as described in Materials and Methods . Statistical analysis by ANOVA and Holm-Sidak. Different letters above bars indicate significant differences P < 0.05 . The graphical data represent mean ( white dotted line ) +/− SD, triangles represent outliers. ( n = 10)

Article Snippet: Paraffin-embedded tumor tissue sections were analyzed by immunohistochemistry using primary antibodies against B-raf or BRAF (Clone VE1, Spring Bioscience, Pleasanton, CA, USA), Bcl-2 (Clone 124, Dako, Carpinteria, CA, USA), p21 (C-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and fibronectin (H-300, Santa Cruz Biotechnology, Santa Cruz, CA, USA).

Techniques: Expressing, Immunohistochemistry, Immunohistochemical staining